RJA
RCEL icon

Raymond James & Associates’s Avita Medical RCEL Stock Holding History

Raymond James & Associates’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,500
Closed -$138K – 4250
2021
Q4 		$138K Sell
11,500
-5,624
-33% -$85.8K ﹤0.01% 3796
2021
Q3 		$303K Buy
+17,124
New +$323K ﹤0.01% 3408
2020
Q2 		– Sell
-2,032
Closed -$63K – 3641
2020
Q1 		$63K Buy
+2,032
New +$84.1K ﹤0.01% 3289

Other funds holding RCEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Raymond James & Associates's RCEL Position: Q1 2022 in Review

Raymond James & Associates sold out of Avita Medical (RCEL) in Q1 2022, closing a stake of 11,500 shares — an estimated $138K sold.

Raymond James & Associates first reported a position in RCEL in Q1 2020 and held it in 3 quarters. The position peaked at $303K in Q3 2021. 69 funds tracked by Wall St. Rank hold RCEL as of Q1 2022.

  • Raymond James & Associates reported no remaining Avita Medical position as of Q1 2022 after selling out during the quarter.
  • Raymond James & Associates sold 11,500 Avita Medical shares in Q1 2022, an estimated $138K.
  • Raymond James & Associates first reported a position in Avita Medical in Q1 2020 and held it in 3 quarters.
  • Raymond James & Associates's Avita Medical position peaked at $303K in Q3 2021.
  • 69 funds tracked by Wall St. Rank held Avita Medical as of Q1 2022.

Based on Raymond James & Associates's 13F filing for Q1 2022, filed 11 May 2022.